The model also showed that in the cohort of HCC patients with SPTBN1 low/IL-6 high, the ratio of SPTBN1 over IL-6 correlates with relapse free survival with a hazard ratio of 0, indicating the loss of SPTBN1 and/or increased level of IL-6 correlates with shorter relapse free survival (p = 0.04901) (Supplementary Table S1-4). This evidence concerns the gene IL6 and hepatocellular carcinoma.